New combo therapy tackles rare brain cancer spread
NCT ID NCT03719768
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This early-phase trial tested the drug avelumab (Bavencio) combined with whole-brain radiotherapy in 16 patients with leptomeningeal disease, a condition where cancer spreads to the lining of the brain and spinal cord. The main goal was to find a safe dose and check for side effects. Researchers also looked at immune cell changes in the spinal fluid.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (Bavencio) and whole-brain radiotherapy
What this could lead to
If it works, this could point toward a new treatment option for leptomeningeal disease, a serious complication of cancer.
What could go wrong
This is a very early, small Phase 1 trial with only 16 participants, focused on safety. It may not show clear benefit, and there are risks of serious side effects like brain bleeding or nerve problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.